CMS
Veracyte Bladder Cancer Test Receives Medicare Coverage
The patient must be a candidate for multiple potential treatments with varying levels of intensity or multiple therapies.
The proposed change would delete payable cancer codes if they contain the word "unspecified" even if the word is included in a code that doesn't impact coverage.
Palmetto Releases Draft LCD for Prostate Cancer Risk Stratification Tests
Under the local coverage determination, tests to help identify patients who may benefit from a prostate biopsy would be covered under certain conditions.
Medicare Administrative Contractor Palmetto Finalizes Coverage of Molecular Testing for Organ Transplant Rejection
Under the policy, covered tests must provide information about active rejection status or cellular or antibody-mediated rejection status.
The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.